Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs’ broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.
External link for Aura Biosciences
80 Guest St
Boston, Massachusetts 02135, US
We are proud to participate in Life Science Cares Boston toy drive to support families in need!
Making the holiday season a little brighter, thanks to toys from Aura Biosciences! Great to see you today at Children's Services of Roxbury, Inc., where the toys will go to local families in need. Thanks for being great #HolidayHelpers!
Aura Biosciences reposted this
Join us TONIGHT for our next Ask the Expert: “Understanding Uveal Melanoma: Screening, Diagnosis and Treatment Options". Hear from Dr. Andrew Stacey, Associate Professor of Ocular Oncology at the University of Washington, and Garth Corner, a uveal melanoma patient and advocate. They’ll discuss UM detection, the importance of screenings like dilated eye exams, treatment options and Garth’s inspiring personal journey. Thank you to Aura Biosciences for their sponsorship of this educational opportunity! It’s not too late to learn and connect—register now: https://lnkd.in/eTsuKVYk
Aura Biosciences reposted this
Spotlight on Prof. Dr. med. Sabine D. Brookman-May : Pioneering Urologic Oncology Prof. Dr. med. Sabine D. Brookman-May is a distinguished urologist and oncologist with over two decades of multidisciplinary experience. She currently serves as the Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, where she leads innovative research and development initiatives. Professional Milestones: Academic Leadership: Prof. Brookman-May holds a professorship in the Department of Urology at Ludwig Maximilian University of Munich, contributing significantly to academic advancements in urologic oncology. Clinical Expertise: As a board-certified urologist with additional certifications in medical tumor treatment and sports medicine, she has authored over 200 peer-reviewed publications, underscoring her commitment to advancing medical knowledge. Industry Leadership: Prior to her current role, she was Vice President of Global Research & Development and Bladder Cancer Development Head at Johnson & Johnson Innovative Medicine, overseeing strategic and clinical operations in bladder cancer research. Prof. Brookman-May's dedication to urologic oncology continues to inspire progress in patient care and medical research. #UrologicOncology #MedicalLeadership #SabineBrookmanMay #AuraBiosciences #MedicalInnovation
We are excited to share that an article discussing the treatment of conjunctival melanoma cell lines with bel-sar was recently published in IOVS, an Association for Research in Vision and Ophthalmology (ARVO) Journal. A special thanks to Dr. Martine Jager for her partnership on the article. A link to the full article can be found here: bit.ly/3YJVyJk
We are pleased to sponsor the Melanoma Research Foundation “Ask the Expert” webinar on Wednesday, November 20 at 7:30 PM ET which will feature a discussion on uveal melanoma. If you are interested in attending, you can register here: https://lnkd.in/eTwGjrW9
As part of our #EyeGetDilated campaign, we encourage you to join a dynamic "Ask the Expert" webinar on Wednesday, November 20 at 7:30 PM ET. This session will dive into an in-depth discussion on uveal melanoma. Learn about current diagnostic challenges, treatment options and hear directly from uveal melanoma patient, Garth Corner. Plus, a Q&A with Dr. Andrew Stacey from the University of Washington and Garth! Thank you to Aura Biosciences for their sponsorship of this educational opportunity. Register now to secure your spot - https://lnkd.in/eTwGjrW9
Aura’s third quarter 2024 financial results and a corporate update are now available. Read the full press release here: bit.ly/3AD2rUB
Urologic Oncology key opinion leader, Gary Steinberg, MD, was interviewed by Urology Times regarding bel-sar’s mechanism of action. Check out the full article here: https://lnkd.in/eturA6S5
This afternoon, Aura announced positive early data from an ongoing Phase 1 clinical trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer. Read the full release here: bit.ly/4dZ9Efu
Join us today at 4:30pm ET for our virtual urologic oncology investor event! Register here: https://bit.ly/4dnqcgD
We are looking forward to J. Jill Hopkins, MD, Aura’s CMO and President of R&D, presentation tomorrow at Eyecelerator @AAO 2024!